PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Piracetam→

Piracetam PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
7491-74-9
Molecular formula
C6H10N2O2
Molecular weight
142.16 g/mol
Drug class
Racetam nootropiccyclic GABA derivative and neuromodulator
Mechanism of action
The mechanism is not fully established. Piracetam modulates neuronal membrane fluidity and membrane-associated signalling and can influence neurotransmission and synaptic plasticity. It does not act as a conventional GABA receptor agonist despite its structural relationship to GABA.
Indications / reported uses
  • Treatment of cortical myoclonus in adults, as an adjunct to other anti-myoclonic therapies, under the UK product label.

Sources: https://www.medicines.org.uk/emc/product/101131/smpc · https://www.ncbi.nlm.nih.gov/books/NBK551680/ · https://www.ema.europa.eu/en/documents/referral/piracetam-article-31-referral-annex-i_en.pdf · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Piracetam PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Piracetam Permitted Daily Exposure (PDE) report (the Piracetam PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Piracetam Occupational Exposure Limit (OEL) report (the Piracetam OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.